Storm Therapeutics Raises $56M Series C for mRNA Methylation Cancer Therapy

Storm Therapeutics raised $56 million in a Series C financing round led by M Ventures and Pfizer Ventures to advance STC-15, an inhibitor of METTL3 — the key enzyme responsible for adding N6-methyladenosine (m6A) modifications to mRNA. By blocking METTL3, STC-15 reverses the differentiation block in acute myeloid leukemia (AML) and other hematologic malignancies by reprogramming the mRNA epitranscriptome. This approach represents a frontier adjacent to direct mRNA therapeutics: targeting endogenous mRNA modification machinery to restore normal gene expression programs in cancer cells. Phase 1 trial data for STC-15 in relapsed/refractory AML have shown promising early signals. The Series C will fund Phase 2 development and expansion into additional m6A-dependent cancers.